Compare FMC Corp (FMC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs IDEXX Laboratories, Inc. — how do they compare? FMC Corp trades at $10.13 (market cap $1.30B), while IDEXX Laboratories, Inc. trades at $572.06 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 35.6× FMC Corp's market cap, and FMC Corp pays a 3.07% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FMC | IDXX | |
|---|---|---|
Market Cap | $1.30B | $46.22B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $766.68 |
52-Week Low | $10.01 | $526.44 |
Enterprise Value | $5.11B | $47.12B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $10.46, down 1.23% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $2.24 billion in 2025, with negative profitability margins, though recent quarters show mixed earnings beats. Analyst consensus is divided, with a $11.60 price target, while recent news highlights revenue challenges and strategic moves like a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and weak revenue trends, but debt reduction efforts and cost controls offer some stability. Key risks include competitive pressures and macroeconomic headwinds, while the current valuation metrics like P/S of 0.4 may attract value investors if operational improvements materialize.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
